NFIB and small cell lung carcinoma: Critically, combining Notch pathway inhibition with chemotherapy attenuated intratumoral heterogeneity and reversed this resistance phenotype.<h4>Conclusions</h4>NFIB plays a paradoxical role in SCLC, serving as both an oncogenic driver and a key regulator of chemoresistance via Notch pathway activation.